Cardlytics enters $50M at-the-market offering agreement with Evercore, BofA, Cantor

Cardlytics, Inc.

Equity Distribution Agreement for up to $50M of common stock, filed March 18, 2024.
Sales agents: Evercore Group, BofA Securities, Cantor Fitzgerald; commission up to 3% of gross proceeds.
ATM shares sold via Nasdaq or other existing trading markets; no minimum obligation to sell.
Offered under existing S-3 shelf registration (declared effective Feb. 9, 2024).
Proceeds used for general corporate purposes, including potential acquisitions or working capital.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cardlytics, Inc. entered into Equity Distribution Agreement with Evercore Group L.L.C., BofA Securities, Inc. and Cantor Fitzgerald & Co. valued at up to a maximum aggregate offering amount of $50.0 million (effective 2024-03-18).

Action: entry
Agreement: atm program
Counterparty: Evercore Group L.L.C., BofA Securities, Inc. and Cantor Fitzgerald & Co.
Value: up to a maximum aggregate offering amount of $50.0 million
Effective: 2024-03-18

Exact text from the filing

On March 18, 2024, Cardlytics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Evercore Group L.L.C., BofA Securities, Inc. and Cantor Fitzgerald & Co. (together, the “Sales Agents”) as sales agents, pursuant to which the Company may issue and sell, from time to time, shares of its common stock (the “ATM Shares”) up to a maximum aggregate offering amount of $50.0 million.

View on SEC.gov

548 material agreements filed in the last 30 days. Browse all material agreements →

Cardlytics, Inc. filing history →

Source: SEC EDGAR

accession 0001666071-24-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.